AI-designed peptides have entered clinical development with diffusion models achieving 34% experimental hit rates against undruggable targets. Machine learning is compressing peptide discovery timelines from 18 months to 6 weeks, but synthesizability and drug-likeness remain unsolved challenges.
Oral peptide delivery remains the holy grail of peptide therapeutics. With Rybelsus generating $4.2B in 2025 and $1.2B in new venture funding, technologies from SNAC to ionic liquids are progressively cracking the bioavailability barrier.
Peptide-drug conjugates combine tumor-homing peptides with cytotoxic payloads for targeted cancer therapy. With 23 clinical programs and 38% response rates in ADC-resistant patients, PDCs offer superior penetration and lower manufacturing costs than antibody-based alternatives.
Between 2027 and 2030, patents on 14 peptide drugs worth $32B will expire. The GLP-1 biosimilar opportunity is immense but capital-intensive. Smart innovators are already shifting to next-generation molecules — the patent cliff is a stress test, not a crisis.
GLP-1/GLP-2 co-agonists like dapiglutide are advancing through Phase II with improved tolerability profiles and complementary gut-barrier benefits. As the obesity market races toward $100B, multi-receptor agonism represents the next competitive frontier.
Antimicrobial peptides are moving beyond therapeutics into food preservation, crop protection, and aquaculture. With engineered nisin variants now commercial in Europe and AMP-expressing crops showing 73% disease reduction in field trials, the non-pharma peptide market is taking shape.
The global peptide therapeutics market crossed 8B in 2025, driven by GLP-1 agonists. With 212 candidates in clinical development and B+ in CDMO capacity expansion underway, peptides are transitioning from a single-class story to a multi-pillar growth narrative.
Continuous-flow solid-phase peptide synthesis is delivering 3.4× faster cycle times and 62% less solvent waste compared to batch methods. With the FDA’s first flow-manufactured peptide approval in January 2026, the technology is crossing from academic promise to industrial reality.
Macrocyclic peptides are breaching the 85% of human proteins once considered undruggable. With 47 candidates in clinical development and AI-driven design achieving 34% hit rates, the modality is entering the therapeutic mainstream.
Antimicrobial peptides are finally moving from academic curiosity to clinical reality. With AMR on the rise, AMPs offer a fundamentally different mechanism that bacteria struggle to resist.
Global SPPS capacity has doubled since 2022, but demand from GLP-1 manufacturing keeps lead times at 12–18 months. Here’s the state of peptide synthesis technology in 2026.
GLP-1 agonists are moving beyond diabetes and obesity into cardiovascular, neurodegenerative, and addiction indications. Here’s what the peptide science tells us about the next decade.
